DS-3939a

DRUG3 trials

Sponsors

Daiichi Sankyo Inc., Daiichi Sankyo

Conditions

Advanced Solid TumorLocally Advanced Non-Small Cell Lung CancerMetastatic Non-Small Cell Lung CancerMetastatic Solid TumorSolid Tumor

Phase 1

First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

RecruitingNCT05875168

Daiichi SankyoAdvanced Solid Tumor, Metastatic Solid Tumor

Start: 2023-08-18End: 2027-02-15Target: 590Updated: 2026-08-12

PHASE 1/2, OPEN-LABEL, MULTICENTER, FIRST IN-HUMAN STUDY OF DS-3939a IN SUBJECTS WITH ADVANCED SOLID TUMORS

RecruitingCTIS2023-507937-14-00

Daiichi Sankyo Inc.Metastatic Solid Tumor, Advanced Solid Tumor

Start: 2025-03-25Target: 114Updated: 2025-09-25

A Study of DS-3939a in Participants With Solid Tumors

Not yet recruitingNCT07739966

Daiichi SankyoSolid Tumor, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer

Start: 2026-10-01End: 2032-01-29Target: 400Updated: 2026-07-31

Related Papers

Data from DS-3939a: A TA-MUC1–Directed Antibody–Drug Conjugate with Broad Antitumor Activity

2026-01-02

DS-3939a: A TA-MUC1-Directed Antibody-Drug Conjugate with Broad Antitumor Activity.

2026-01-011 citations

A phase 1/2, first-in-human study of DS-3939a in patients with advanced solid tumors: A new DXd ADC targeting TA-MUC1.

Journal of Clinical Oncology2024-06-013 citations

Abstract CT291: A phase 1/2, first-in-human study of DS-3939a in patients with advanced solid tumors: A new DXd ADC targeting TA-MUC1

Cancer Research2024-04-05

Abstract 6579: DS-3939a, a novel TA-MUC1-targeting antibody-drug conjugate (ADC) with a DNA topoisomerase I inhibitor DXd, exhibits potent antitumor activity in preclinical models

Cancer Research2024-03-222 citations